HER2-low Breast Cancer Clinical Trials

14 clinical trials for HER2-low Breast Cancer across international registries, including 10 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors — RECRUITING · PHASE1
• Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study — RECRUITING · PHASE2
• Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer — RECRUITING
• A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer — RECRUITING · PHASE3
• A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH) — RECRUITING
• HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC — RECRUITING
• TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd — RECRUITING · PHASE2
• Distribution of the Homologous Recombination-related (HRR) Genesmutationsand HRD in Breast Cancer — RECRUITING
• PRE-I-SPY Phase I/Ib Oncology Platform Program — RECRUITING · PHASE1
• Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer — RECRUITING
• A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 — TERMINATED · PHASE1
• A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer — NOT_YET_RECRUITING · PHASE2
• Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer — COMPLETED
• ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer — WITHDRAWN · PHASE1

Refine this search